C-I3WFCyclarity Therapeutics
cyclodextrins, cholesterol clearance, plaque removal
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-I3WF
C-I3WFC-I3WFcyclodextrins, cholesterol clearance, plaque removal
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The goal of this clinical trial is to learn if UDP-003 is safe in healthy human participants and patients, assess the pharmacokinetics (PK)/pharmacodynamics (PD) of UDP-003 in healthy human participants and patients and its potential efficacy in patients. Researchers will compare UDP-003 to a placebo in a blinded manner. This first in human, randomised, double-blind, placebo-controlled, prospective, single-centre trial with a modular dose-finding design will be conducted in 3 parts: * Part 1: 6 cohorts of 6 healthy participants receiving Single Ascending Doses (SADs), * Part 2: 3 cohorts of 12 healthy participants receiving Multiple Ascending Doses (MADs) (6 doses over 16 days), * Part 3: 1 cohort of 12 participants diagnosed with acute coronary syndrome (ACS; non-ST elevation myocardial infarction \[NSTEMI\] or unstable angina) at least 12 months post-event receiving multiple doses (6 administrations of the 25 mg/kg dose over 16 days). The planned duration of the study for each participant will be: * 4 weeks for SAD Participants (1-day treatment period, 4-week safety follow-up) * 6 weeks for MAD Participants (16-day treatment period,4-week safety follow-up) * 28 weeks for MD Patients (6-week treatment period, 6-month safety follow-up) Prior to participants being randomised to panels of increasing doses, all safety data will be reviewed for completed panels.
LongX presents our Entrepreneurship Workshop, featuring Dr. Amelia Anderson, Head of Scientific Computing and cofounder at Cyclarity Therapeutics. Dr. Anderson will share her journey from being a SENS Research Foundation (SRF) Summer Scholar (Class of 2017) to being a biotech cofounder. Her talk covered her experience building a company stemming from her research, and the challenges and struggles that come with building a spin-off in longevity biotech. The workshop wraps up with questions from the Xplore Program Fellows from LongX. This event was part of our "Building in Biotech" 3-part workshop. --- About LongX ⭐ LongX was launched in 2023 as a platform for youth interested in longevity. We prioritize fostering innovation and interdisciplinary collaboration, aiming for both short-term impact and long-term progress. We encourage exploration beyond traditional roles and aim to equip future experts with the skills to drive progress. Our Substack provides regular articles on our thou
From machine learning to virtual reality, Cyclarity is leveraging the key tools in the fight against atherosclerosis. Cyclarity Therapeutics is targeting atherosclerosis and hoping to do something about cardiovascular disease’s ranking as the world’s number one killer by reducing incidences of heart attack and stroke through a simple and affordable preventive therapy. The company’s platform uses rationally-designed cyclodextrin molecules that remove arterial plaque by clearing the non-degradable oxidised cholesterol that accumulates within cells in the arterial walls. We wanted to find out more about how these molecules were designed, so we sat down with Head of Scientific Computing & Co-Founder Amelia Anderson to find out more about how it all works. Plus she let us road-test her VR program! ------------------------------ Visit Longevity.Technology - https://bit.ly/3PwtH8Y Follow Longevity.Technology on: Twitter - https://bit.ly/3AMIXuq Facebook - https://bit.ly/3z8H1v5 Instagram
How a novel cyclodextrin platform is tacking bad guy cells and reinvigorating them to be guardians of the immune system. Cyclarity Therapeutics has atherosclerosis firmly in its sights; with tech that removes arterial plaque by clearing the non-degradable oxidised cholesterol that accumulates within cells in the arterial walls, the company is well-placed to deliver its long-term goal of simple and affordable preventive therapy for the world. Cardiovascular disease is the world's number one killer, but many people don't even know they have atherosclerosis as the first indication can often be a fatal or life-impacting event such as a heart attack or stroke. The first true disease-modifying treatment, Cyclarity's rationally-designed cyclodextrin molecule (UDP003) is set to change all that. We're excited by Cyclarity's platform, so we were delighted to sit down with CEO of Corporate Affairs Mike Kope, CEO of Scientific Affairs Dr Matthew ‘Oki’ O’Connor, Director of Biology Dr Daniel M
He has served as the University of Michigan's Intellectual Property Counsel ... Cyclarity Therapeutics, Inc. develops easy-to-use drugs that ...
... ASCO 2024 and ASCO GI 2024. Bold Therapeutics expects to initiate pivotal ... Cyclarity Therapeutics, Inc. is pursuing a mission to treat, cure, and ...
... ASCO · ASD Therap · Asdera · A-SEEDS · Aseer Central Hospital · AseptiScope ... Cyclarity Therapeutics · Cycle Group · Cyclenium · Cyclerion · Cyclica · Cyclomics
Cyclarity Therapeutics is on a mission to deliver affordable therapy ... ASCO GI: https://m.youtube.com/watch?v=4lTX7y16pt0 Mipsagargin ...
Cyclarity Therapeutics, a SENS Foundation spinout, developed a medication ... American Association for Cancer Research annual meeting, 2022), while ...
Breaking News: Read BioWorld's AACR 2026 coverageSee today's BioWorld Science ... Cyclarity Therapeutics Inc. has obtained regulatory approval to ...
... Gerontological Society of America. Dr. Justice is the recipient of the ... Matthew 'Oki' O'Connor, PhD. CEO of Scientific Affairs, Cyclarity Therapeutics.
... Gerontological Society of America. Through shared leadership and ... Cyclarity Therapeutics. . Follow · The Dog Aging Institute. . Follow.
Exciting news! MBT is thrilled to announce a brand new partnership with Cyclarity Therapeutics!
... Gerontological Society of America and the ... Chief Executive Officer Of Scientific Affairs Director Cyclarity Therapeutics, Cyclarity Therapeutics.
The research identifying the 27 events was presented at the Alzheimer's Association International Conference in London. ... Cyclarity Therapeutics.
... Alzheimer's Association International Conference - AAIC 2017 July 16 ... Cyclarity Therapeutics and Paul Camilleri. 2 reactions. Dmitry ...
... (AAIC), OncoC4, Inc. rather unexpectedly took to the neurology stage ... Plus, see how new findings strengthen Cyclarity Therapeutics ...
Explore Cyclarity Therapeutics, Inc. with its drug pipeline, therapeutic ... About the Rejuvenation Startup Summit 2024 The Rejuvenation Startup Summit ...
Cyclarity Therapeutics | Cyclarity Therapeutics presents at Rejuvenation Startup Summit ... Rejuvenation Startup Summit. Summarized by AI ...
Mike Kope presents at the Rejuvenation Startup Summit 2022. By Cyclarity Therapeutics · November 15, 2022. Mike-RS2022-1.0. Tap to unmute.
... JPM Healthcare Conference Week. We are Cyclarity Therapeutics, working to reverse atherosclerosis, based at the Buck Institute for Research ...
Cyclarity Therapeutics is pleased to announce regulatory approval to begin ... BIO International Convention in Boston, look for our team, we'll be ...
About BIO International Convention · Venue · Future dates · Attendee Policies ... Cyclarity Therapeutics. Invest Puerto Rico. white square ...
Cyclarity Therapeutics Secures Approval for First-in-Human Clinical Trial. Cyclarity Therapeutics ... BIO International Convention in Boston, look for our ...
Co-CEO at Cyclarity Therapeutics. 9mo. Report this post; Close menu. I'll be speaking at the Vitalist Bay Summit this weekend in berkeley. https://lnkd.in ...
Vitalist Bay 2026 Returns to Berkeley May 14–17. Picture of ... (Cyclarity Therapeutics) • Marco Quarta (Rubedo Life Sciences) • Matt ...
Cyclarity Therapeutics (@Cyclarity) ... Cyclarity founder Matthew "Oki" O'Connor will be speaking at the Vitalist Bay Summit this weekend in berkeley.
Cyclarity Therapeutics. Max Marty. Founder The Cryosphere / Cryonics ... Where is Vitalist Bay being held? Vitalist Bay is taking place from ...
Cyclarity Therapeutics advances series A tranche 2 funding to accelerate breakthrough cardiovascular treatment ... Insights from the 4th longevity investors ...
... Longevity Investors Conference 2024! Dr. Sinclair is a trailblazer in ... Cyclarity Therapeutics. . Follow · Unicon: The International ...
Longevity Investors Conference • 11. Longevity Leaders Congress • 12 ... Cyclarity Therapeutics, as a speaker for the #RejuvenationStartupSummit ...
... Cyclarity Therapeutics removes arterial plaque by clearing the non ... RAADfest 2025 in Las Vegas, recorded on July 12, 2025, and ...
RAADfest 2024 speakers will report more breakthroughs on longevity than any other conference ever ... RAADfest ... Cyclarity Therapeutics.
... Cyclarity Therapeutics discuss Cyclarity's ... Cyclarity Therapeutics removes arterial plaque by ... Find out more about RAADfest at [https://raadfest.
Cyclarity Therapeutics, Inc. today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the ...
... Cyclarity Therapeutics; Gary J Alan Co-Founder of @ ... #aging #longevity #science #health. more. View 1 comment · April 24. OCR. ARDD ...
Welcome back Vitalians and please join us in congratulating the Cyclarity Therapeutics (CTx) team for passing the VitaDAO token holder vote!
The Aging Research and Drug Discovery conference ... The Aging Research and Drug Discovery conference is ... Cyclarity Therapeutics · . 1 · · The Youth ...
Matthew "Oki" O'Connor- Cyclarity Therapeutics. 310 views · 2 ... Go to channel ARDD · Parminder Singh at ARDD2023: Taurine deficiency ...
Dr. Amelia Anderson. Head of Scientific Computing & Co-Founder at Cyclarity Therapeutics. Dr. Amelia Anderson's Executive Work History.
Have you read our most recent paper about naming CDs? Just the line-up of authors might be worth a look: Cyclarity Therapeutics: Amelia Anderson, Matthew “Oki” ...
... Amelia Anderson, the Co-Founder and Head of Scientific Computing at Cyclarity Therapeutics. In this episode, we discuss what sparked Amelia's interest in ...
Amelia Anderson's Post ... That's awesome! Congratulations to the whole team! ... Exciting news and congratulations to Cyclarity Therapeutics!! Here's to 2025! :).
... Amelia Anderson, the Co-Founder and Head of Scientific Computing at Cyclarity Therapeutics.In this episode, we discuss what sparked Amelia's ...
Mike Kope, CEO of Cyclarity – prevents age-related conditions such as atherosclerosis, heart attack, and stroke by addressing the root cause; Aaron Cravens ...
Investments include Cellvie, Cyclarity, Revel, Elastrin, LIfT, and MoglingBio. Learn more at https://www.forever-healthy.org. For free media ...
... Affairs Matthew O'Connor. “As we advance into being a clinical stage company, Cyclarity is focused on bringing truly disease-modifying ...
To learn more, visit https://cyclaritytx.com/. Cyclarity Therapeutics Co-Founders Dr. Amelia Anderson Matthew OConnor and Michael Kope From Left ...
Cyclarity develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke.
News & Publications · Supplementary Material · Investors · Contact Us · Career Opportunities · Home · Our Science · Team · News & Publications · Supplementary ...
Corporate Status: Launched from a research program begun in 2016, since founding in 2019 we have raised $14 million in two private equity seed rounds. Our IP ...
Cyclarity Therapeutics Announces Clinical Advisory Board. Cyclarity Therapeutics ... Prediman K. Shah, Director of Inpatient Cardiology and the ...
Cyclarity Therapeutics would like to thank its new Clinical Advisory Board: - Dr. Prediman K. Shah, Director of Inpatient Cardiology and the Coronary Care Unit ...
Cyclarity Therapeutics would like to announce its new Clinical Advisory Board: - Dr. Prediman K. Shah, Director of Inpatient Cardiology and the Coronary ...
Cyclarity Therapeutics, Inc. today announced its newly formed ... Prediman K. Shah, Director of Inpatient Cardiology and the Coronary ...
He has served as the University of Michigan's Intellectual Property Counsel ... Cyclarity Therapeutics ... Underdog becomes Cyclarity Therapeutics. Longevity ...
Cyclarity Therapeutics (CTx) engineers cyclodextrin (CD) molecules ... He has served as the University of Michigan's Intellectual Property Counsel ...
1991 - 1999 Intellectual Property Counsel @ University of Michigan. see less ... Cyclarity Therapeutics. Michael Kope brings experience from previous roles at ...
He received his J.D. from the University of Michigan in 1990. He has served as the University of Michigan's Intellectual Property Counsel; Director of Corporate ...
Cyclarity Therapeutics Logo Cyclarity Therapeutics. Section: Overview. Actions ... Michael Kope: CEO Corporate Affairs. Past Role: SENS Foundation, Founding ...
Meet Michael Kope, our CEO of Corporate Affairs, at the Bio Investor Forum in San Francisco, October 17-18. Learn about Cyclarity's novel approach to curing ...
0 likes, 0 comments - cyclarity on December 21, 2022: "CEO, Corporate Affairs Mike Kope discusses company strategy and the work to prevent ...
... Corporate Affairs CEO of Cyclarity. Cyclarity expects to conduct the UDP-003 Phase 1 trial under the direction of Dr. Nicholls and VHI, and is exploring ...
Michael K. Kope is the Chief Executive Officer, Corporate Affairs at Cyclarity Therapeutics, bringing extensive leadership experience in the pharmaceutical ...
Contact: Mike Kope CEO of Corporate Affairs Cyclarity Therapeutics, Inc. [email protected]. Categories News, Science, Team · Cyclarity Therapeutics ...
Cyclarity Therapeutics, Novato. 796 likes. Cyclarity Therapeutics ... Daniel Clemens: VP of Biology - Amelia Anderson: Head of Scientific Computing - Dr.
Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies ...
Contact: Mike Kope CEO of Corporate Affairs Cyclarity Therapeutics, Inc. [email protected]. Categories Investors, News Tags Press Release · Cyclarity ...
Amelia Anderson is the Co-Founder and Head of Scientific Computing of Cyclarity Therapeutics. She previously worked at SENS Research Foundation as a ...
Amelia Anderson, PhD, is the Scientific Computing Head at Cyclarity Therapeutics, specializing in computational biochemistry.
Cyclarity Therapeutics, 8001 Redwood Blvd Novato, CA 94945, USA ... Electronic address: [email protected]. 2 Department ...
... Amelia Anderson, the Co-Founder and Head of Scientific Computing at Cyclarity Therapeutics. Episode 3 - Amelia Anderson cover. Episode 3 - Amelia Anderson ...
Amelia Anderson. Director of Computational Chemistry @ Cyclarity Therapeutics | PhD, Materials Science & Applied Physics | MS, Theoretical Chemistry and ...
Bill Liao. Chairman of the Board. Independent Director and Chair of the Investment Committee of Ki Tua Fund, General Partner at SOSV, Co-Founder of IndieBio ...